Volatile earnings
Profit has swung sharply over 7 years (from ₹-1,878 to ₹4,437) — one year is a weak guide to the earnings power.
Importance 62 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Profit has swung sharply over 7 years (from ₹-1,878 to ₹4,437) — one year is a weak guide to the earnings power.
Importance 62 / 95 · growth
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 3.54×).
Importance 55 / 95 · cash quality
Net worth compounded at 12.6% a year over 7 years (₹18,003 → ₹41,269).
Importance 53 / 95 · financial health
Classified by the exchange under Commodities › Chemicals › Fertilizers & Agrochemicals › Pesticides & Agrochemicals.
Peer set used on this page: 2 pesticides & agrochemicals.
Revenue fell 5.7% a year over 7 years, from ₹8,660 cr in FY2019 to ₹5,748 cr in FY2026 (includes the Feb 2019 acquisition of Arysta LifeScience). Net profit grew 9.9% a year over the same period.
Profit has swung sharply over 7 years (from ₹-1,878 to ₹4,437) — one year is a weak guide to the earnings power.
Rule EARNINGS_VOLATILE
Revenue compounded at 13.1% a year over 7 years (₹21,837 → ₹51,839) — though FY2020 saw a one-off step-change of 64% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit rose 170.7% to ₹2,220 — but FY2025 was a depressed ₹820 (vs a ~₹2,837 historical norm), so this is a recovery. Profit has compounded 5.6% a year over 7 years.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹11,860 cr (down 1.3% on the same quarter last year) and net profit ₹452 cr (down 26.1%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹452 cr, down 26.1% from ₹612 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 net profit declined 26.1% while revenue declined 1.3% vs the same quarter last year — a gap of 24.8 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
Q2 FY27 revenue was ₹11,860 cr, up 16.5% from ₹10,181 cr in the previous quarter (Q1 FY27).
Rule QTR_REVENUE_SEQUENTIAL_CHANGE
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 10,907 | +10.3% | 853 | −153.1% | 7.8% |
| Q4 FY25 | 15,573 | +10.6% | 1,079 | −1448.8% | 6.9% |
| Q1 FY26 | 9,216 | +1.6% | −176 | −66.6% | −1.9% |
| Q2 FY26 | 12,019 | +8.4% | 612 | −204.6% | 5.1% |
| Q3 FY26 | 12,269 | +12.5% | 490 | −42.6% | 4.0% |
| Q4 FY26 | 18,335 | +17.7% | 1,294 | +19.9% | 7.1% |
| Q1 FY27 | 10,181 | +10.5% | −73 | −58.5% | −0.7% |
| Q2 FY27 | 11,860 | −1.3% | 452 | −26.1% | 3.8% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 22.5% in FY2026, against 16.2% in FY2019. ROE was 30.1% and ROCE 1.5% in FY2025.
ROE of 5.6% is below the pesticides and agrochemicals median of 9.0%.
Rule ROE_BELOW_PEER_MEDIAN
ROE rose from 2.3% to 5.6% — but FY2025 was a depressed year, so this is a rebound rather than a step-up.
EBITDA margin improved from 17.3% to 19.2% of revenue.
EBITDA margin has ranged from 11.7% to 22.3% over 7 years and sits at 19.2% now.
It had little or no debt in FY2025 (debt-to-equity 0.05x). Operating cash flow was -2.86x net profit.
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 3.54×).
Rule CFO_CONSISTENTLY_EXCEEDS_PAT
Net worth compounded at 12.6% a year over 7 years (₹18,003 → ₹41,269).
Free cash flow has been positive in 6 of the last 6 years.
Operating profit covers interest only 1.97× (FY2026).
Its peer group is too small for a meaningful ranking.
Ranked against 2 pesticides & agrochemicals (FY2026, consolidated). No peer-relative rule fired for this company.
Not enough peers in this set report the underlying metrics yet for a ranking.
On the trailing twelve months. Last full year: P/E 21.8× · P/S 0.9× · ROE 5.6%.
The share price is down 24.1% over 1 year, up 1.6% over 3 years (0.5% a year) and down 22.9% over 5 years (−5.1% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 29.0% below its 52-week high.
Long-term price performance is shown above.
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8,660 | 9,641 | 11,345 | 16,449 | 18,783 | 5,398 | 5,330 | 5,748 |
| Total income | 9,220 | 10,147 | 11,458 | 17,080 | 19,245 | 6,202 | 5,477 | 6,654 |
| EBITDA | 1,399 | 1,711 | 1,733 | 2,688 | 2,746 | 1,205 | 299 | 1,296 |
| Profit before tax | 486 | 538 | 434 | 1,261 | 1,284 | 931 | 2,045 | 1,013 |
| Net profit | 405 | 461 | 220 | 1,176 | 975 | 1,208 | 2,939 | 785 |
| EPS (₹) | 8.0 | 6.0 | 2.9 | 15.4 | 13.0 | 16.1 | 38.1 | 9.5 |
| Net worth | 7,972 | 8,024 | 7,786 | 8,201 | 7,068 | 7,530 | 12,021 | — |
| Total debt | 1,365 | 997 | 1,087 | 1,665 | 566 | 1,827 | 570 | — |
| Operating cash flow | — | — | 1,820 | 2,349 | 1,667 | −411 | −923 | −2,243 |
| Free cash flow | — | — | 656 | 1,303 | 560 | −1,073 | −1,178 | −2,279 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | 11.3 | 17.7 | 45.0 | 14.2 | -71.3 | -1.3 | 7.8 |
| Profit growth YoY | — | 13.8 | -52.3 | 434.5 | -17.1 | 23.9 | 143.3 | -73.3 |
| Profitability | ||||||||
| EBITDA margin % | 16.2 | 17.7 | 15.3 | 16.3 | 14.6 | 22.3 | 5.6 | 22.5 |
| Net margin % | 4.4 | 4.5 | 1.9 | 6.9 | 5.1 | 19.5 | 53.7 | 11.8 |
| Return on equity % | 5.1 | 5.8 | 2.8 | 14.7 | 12.8 | 16.6 | 30.1 | — |
| Return on capital % | 7.2 | 8.9 | 8.4 | 17.5 | 20.5 | 12.7 | 1.5 | — |
| Leverage & cash | ||||||||
| Debt to equity | 0.17 | 0.12 | 0.14 | 0.20 | 0.08 | 0.24 | 0.05 | — |
| Cash flow ÷ profit | — | — | 8.27 | 2.00 | 1.71 | -0.34 | -0.31 | -2.86 |
| Current ratio | 1.14 | 1.12 | 1.07 | 1.14 | 1.06 | 0.84 | 1.62 | — |